Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck’s $11.5bn Acceleron Buy Partially Fills Future Keytruda Revenue Gap

Deal Expands Existing Cardiovascular Portfolio

Executive Summary

The company announced the biggest biopharma M&A deal of the year so far, but Merck will need more large deals to manage declining sales when its top-selling product faces biosimilars in 2028. 

You may also be interested in...



With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy

The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.

Merck & Co. Heads Into A Year Of Portfolio Expansion

The company expects new products like the pneumococcal vaccine V116, the PAH treatment sotatercept and the ADC patritumab deruxtecan will begin contributing to revenue growth in the near term.

BMS Broadens Market, De-Risks Long-Term Revenue Potential For Reblozyl

As a first-line treatment for anemia in patients with myelodysplastic syndromes, Reblozyl is approved for indications that will account for 75%-80% of the $4bn-plus in sales Bristol has forecast by 2029.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC145163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel